Supplementary Materials

Cellular growth and viability of the CIKs during expansion are illustrated in the Supplementary Materials section (Figure S1 and S2 respectively). Release criteria for drug product CIK cells are indicated in the Table S1.

| QUALITY CONTROLS          | ACCEPTANCE CRITERIA |
|---------------------------|----------------------|
| Cellular Viability        | >80%                 |
| Cellular Identity CD45+CD3+ | >80%               |
| CD45+CD3+CD56+            | ≥15%                 |
| Sterility                 | negative             |
| Mycoplasma                | absent               |
| LAL test                  | <0.5 EU/ml           |

Table S1. Release criteria for drug product CIK cells

![Cell Growth (Absolute Cell Number)](image)

Figure S1. Cellular growth expressed as an absolute number in millions of cells for the 4 batches during the expansion process.
Figure S2. Viability trend expressed in percentages for the 4 batches during the expansion process.